Unresectable Liver Metastases

Use of Intera 3000 HAI Pump for colorectal cancer patients with Unresectable Liver Metastases
In a study at University of Pittsburgh Medical Center, patients with unresectable liver metastases who received an Intera 3000 HAI Pump with floxuridine, and systemic chemotherapy had a median overall survival of 32.8 months. Patients treated with systemic chemotherapy alone had a median overall survival of 15.3
months.

In a case-control study of 86 patients with liver only colorectal cancer metastases (CLM):

  • Patients treated with the Intera 3000 HAI Pump with floxuridine, and systemic chemotherapy had a median overall survival of 32.8 months. Patients treated with systemic chemotherapy alone had a median overall survival of 15.3 months (P < 0.0001).
  • While this was not a randomized controlled trial, both groups of patients were similar in demographics, had extensive disease in the liver, and had received prior systemic chemotherapy. When comparing groups, the following characteristics were similar (P > 0.05).
    • Liver tumor burden: median number of lesions in the HAI group of 13.5 vs. 15 in the non-HAI
    • Percentage of liver tumor replacement was 37.5 in the HAI vs. 40 % in the non-HAI
    • Size of largest lesion was 5.6 in the HAI vs. 6 cm in the non-HAI [1]

Study limitation: small sample size and retrospective analysis with potential selection bias. 

Adjuvant Therapy

[1] Dhir M, Jones HL, Shuai Y, et al : Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study. Ann Surg Oncol (2017) 24 :150-158

24/7 Clinical Call :

USA & Canada (800) 660-2660 
Europe: +1 (781) 461-5627
© Copyright 2022 Intera Oncology. All Right Reserved Designed by Medtech Momentum
TLB-90027 Rev A